Atlas Trials

Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC)

Clinical trial NCT02973997 · COMPLETED

Trial details

NCT number
NCT02973997
Sponsor
Academic and Community Cancer Research United
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Columnar Cell Variant Thyroid Gland Papillary CarcinomaFollicular Variant Thyroid Gland Papillary CarcinomaMetastatic Thyroid Gland Follicular CarcinomaMetastatic Thyroid Gland Papillary CarcinomaPoorly Differentiated Thyroid Gland CarcinomaRecurrent Differentiated Thyroid Gland CarcinomaRecurrent Thyroid Gland Follicular CarcinomaRecurrent Thyroid Gland Papillary CarcinomaStage III Differentiated Thyroid Gland Carcinoma AJCC v7Stage III Thyroid Gland Follicular Carcinoma AJCC v7Stage III Thyroid Gland Papillary Carcinoma AJCC v7Stage IV Thyroid Gland Follicular Carcinoma AJCC v7
Start date
2018-02-07
Primary completion
2022-08-15
Enrollment
57

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.